BONUS DIGITAL CONTENT

Adult Preventive Health Care Sc	hedul	e: Re	comr	nend	atior	is fro	m the	USP	STF (as of J	une 18	, 2021,)		
To be used in conjunction with USPSTF recom	nmendat	ion sta	tement	s (for a	ddition	al detai	ls see ta	ables a	nd refe	rences	at http	s://ww	w.aafp.	org/afp	/PHC
Only grade A/B recommendations are show	n														
Age	18	21	24	25	35	40	45	50	55	59	65	70	74	75	80
USPSTF screening recommendations															
Alcohol misuse ¹	(B)														
Depression ²	(B)														
Hypertension ³	(A)														
Obesity/weight loss ⁴	(B) if	BMI 30) kg pei	r m² or g	greate	r									
Tobacco use and cessation ⁵	(A)														
Hepatitis C virus infection ⁶	(B)														
HIV infection ⁷	(A)											(A) <u>if</u>	at incr	eased r	<u>risk</u>
Hepatitis B virus infection ⁸	(B) <u>if</u>	at incr	eased	<u>risk</u>											
Syphilis ⁹	(A) <u>if</u>	at incr	eased	<u>risk</u>											
Tuberculosis ¹⁰	(B) <u>if</u>	at incr	eased	<u>risk</u>											
BRCA gene risk assessment ¹¹	(B) if	approp	oriate p	ersonal	or fan	nily hist	ory of E	BRCA-	related	cance	r or and	cestry			
Chlamydia and gonorrhea ¹²	(B) if	sexuall	y active	(B) <u>if</u>	at incr	eased i	isk								
Intimate partner violence ¹³				bearing											
Cervical cancer ¹⁴						ns and s	creenir	ng inte	rvals						
Abnormal glucose/type 2 diabetes mellitus ¹⁵			T		i i		overwe								
Colorectal cancer ¹⁶							(B)	(A)							
Breast cancer ¹⁷							(-/		ennial s	creeni	ina				
Lung cancer ¹⁸												and ci	urrent o	or form	ner
-ung ounce.											t 15 ye				
Osteoporosis ¹⁹								(B) if postmenopausal and elevated risk							
Abdominal aortic aneurysm ²⁰											(B) if	an "eve	r smok	er"	
Unhealthy drug use ²¹	(B)														
USPSTF preventive therapies recommendati	ions														
HIV preexposure prophylaxis ²²		at high	n risk o	f HIV in	fectio	n									
Primary prevention of breast cancer ²³							incer ar	nd low	risk for	side et	ffects				
Folic acid supplementation ²⁴				nceivin											Τ
Statins for primary prevention of CVD ²⁵	(7 (7 11	Сарав		Treetviii.	9	(R) se	e criter	ia on n	4						
Aspirin for primary prevention of CVD and						(D) 30	.c critci		·	<u>Ω-</u>					
colorectal cancer ²⁶								` '	CVD ris						
Fall prevention in community-dwelling older adults ²⁷												ercise ased fa	interve Ill risk	ntions	if at
USPSTF counseling recommendations															
Sexually transmitted infection prevention ²⁸	(B) <u>if</u>	at incr	eased	risk_											
Diet/activity for CVD prevention ²⁹	(B) ad	dults w	ith CVI	D risk fa	ctors										
Skin cancer prevention ³⁰	(B) if fair skinned														
Healthy weight gain in pregnancy ³¹	(B) al	l pregr	nant wo	men											
									1						
	Norn	nal risk	1	Nith spe	cific ri	sk facto	r F	Recomr	nendati	ion gra	des				
Legend							ļ.	A R	ecomn	nende	d (likely	signifi	cant be	enefit)	
Legend Recommendation for men and women															
Recommendation for men and women							E	3 R			-		rate be		
							E	R C D	o not ι	use rou	ıtinely (benefit	is likel	y small	
Recommendation for men and women							E	R C D	o not ι	use rou	ıtinely (benefit		y small	

HIV RISK FACTORS

IV drug use Men who have sex with men

Other STI

Requesting STI testing
Sex exchanged for drugs or money

Sex with individuals who are IV drug users, bisexual, or HIV positive

Unprotected sex, including anal intercourse

Patients in whom to consider PrEP:

Sexually active men who have sex with men who have any of the following:

Sexual relationship with serodiscordant partner

Inconsistent use of condoms during anal sex

Syphilis, gonorrhea, or chlamydia infection in past six months

Sexually active heterosexual patients with any of the following:

Sexual relationship with serodiscordant partner

Inconsistent use of condoms with high-risk partner

Syphilis or gonorrhea infection in past six months

Injection drug users with any of the following:

Shared drug-injection equipment

Risks of infection through sex (see above)

IV = intravenous; PrEP = preexposure prophylaxis; STI = sexually transmitted infection.

HEPATITIS B INFECTION RISK FACTORS

HIV infection Infected sex partner Intravenous drug use Living with an infected individual Men who have sex with men

Origin from regions* with prevalence ≥ 2%

U.S.-born children of immigrants
from regions* with prevalence ≥ 8%, if
unvaccinated

SYPHILIS RISK FACTORS

High-risk sexual behaviors Incarceration Men who have sex with men
Sex exchanged for drugs or money

Local prevalence

TUBERCULOSIS RISK FACTORS

Health professionals*
Homelessness, including former
Immunosuppression*

Prisoners, including former Residents of high-risk regions, including former

*—Evidence for screening not reviewed by the USPSTF because this is standard practice in public health and standard of care for patients with immunosuppression, respectively.

CHLAMYDIA AND GONORRHEA RISK FACTORS

New or multiple sex partners
Other STI, including history of STI
Partner with STI

Partners who have multiple sex partners

STI = sexually transmitted infection.

Sex exchanged for drugs or money

Sexually active adolescents

Unprotected sex or inconsistent condom use

CARDIOVASCULAR DISEASE RISK FACTORS

Atherosclerotic cardiovascular disease risk ≥ 7.5% Dyslipidemia Hypertension or elevated blood pressure

Metabolic syndrome

BREAST CANCER RISK FACTORS

Consider use of a risk-assessment model for patients with a history of biopsy or positive family history

SEXUALLY TRANSMITTED INFECTION RISK FACTORS

Similar to those risk factors listed previously for sexually transmitted infections; consider local and population-based prevalence in individual risk assessment

^{*—}Risk of regions can be found at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm.

Adult Preventive Health Care Schedule: Recommendations from the USPSTF

Grade A/B Recommendations (with Associated Grade C/D/I Recommendations):

Alcohol misuse screening¹

(B) Screen adults and provide brief behavioral interventions for risky alcohol use

Depression screening²

(B) Screen adults with systems for evaluation and management

Hypertension screening³

(A) Screen adults; exclude white coat hypertension before starting therapy

Obesity/weight loss screening4

(B) Refer adults with obesity to intensive behavioral interventions for weight loss

Tobacco use and cessation screening⁵

- (A) Screen all nonpregnant adults and provide behavior therapy and U.S. Food and Drug Administration—approved intervention therapy for cessation
- (A) Screen all pregnant women and provide behavior therapy.
- (I) IETRFOA electronic nicotine delivery systems for tobacco cessation
- (I) Pharmacotherapy for tobacco cesation in pregnant persons

Hepatitis C virus infection screening⁶

(B) Screen adults 18 to 79 years of age

HIV infection screening⁷

- (A) Screen individuals 15 to 65 years of age
- (A) Screen older and younger persons who are at increased risk

Hepatitis B virus infection screening8

(B) Screen adolescents and adults at high risk

Syphilis screening9

(A) Screen individuals at increased risk

Tuberculosis screening¹⁰

(B) Screen individuals at increased risk

BRCA-related cancer risk assessment/screening11

- (B) Use a familial risk assessment tool (evaluated assessment tools listed in full text) in women with either:
 - Personal or family history of breast, ovarian, tubal, or peritoneal cancers
 - Ashkenazi Jewish ancestry (i.e., ancestry with increased risk of BRCA mutation)

For positive risk tools, offer genetic counseling and genetic testing, if indicated.

(D) Recommend against screening for patients without appropriate family history, personal history, or ancestry

Chlamydia and gonorrhea screening¹²

- (B) Screen sexually active women 24 years and younger, and women at increased risk who are 25 years and older
- (I) IETRFOA screening sexually active men

Intimate partner violence screening¹³

- (B) Screen women of childbearing age and refer to appropriate services
- (I) IETRFOA screening all vulnerable and older adults for abuse or neglect

Cervical cancer screening¹⁴

(A) Screen women

- 21 to 29 years of age every three years with cytology alone
- Frequency of screening may increase to every five years for women 30 to 65 years of age with cytology and high-risk human papillomavirus cotesting or high-risk human papillomavirus testing alone
- (D) Recommend against screening in women
 - 20 years and younger
 - Older than 65 years if adequately screened previously and no increased risk of cervical cancer
 - With hysterectomy (including cervix) without history of cervical intraepithelial neoplasia grade 2 or 3 or cervical cancer
 - Younger than 30 years with human papillomavirus testing alone or in combination with cytology

Abnormal glucose and type 2 diabetes mellitus screening¹⁵

(B) Screen adults 40 to 70 years of age who are overweight or obese and refer patients with abnormal glucose levels for intensive counseling for healthy diet and exercise

Colorectal cancer screening¹⁶

- (A) Screen patients 50 to 75 years of age with fecal occult blood (or immunochemical) test, sigmoidoscopy, colonoscopy, computed tomography colonography, or multitargeted stool DNA test
- (B) Screen patients 45 to 49 years of age with fecal occult blood (or immunochemical) test, sigmoidoscopy, colonoscopy, computed tomography colongraphy, or multitargeted stool DNA test
- (C) Selectively offer screening to patients 76 to 85 years of age

Breast cancer screening¹⁷

- (B) Biennial screening mammography in women 50 to 74 years of age
- (C) Screening is an individualized decision for women 40 to 49 years of age
- (I) IETRFOA
 - Mammography after 75 years of age
 - Screening with digital breast tomosynthesis
 - Adjunctive screening in women with dense breast tissue and negative screening mammogram

Lung cancer screening18

(B) Screen annually with low-dose computed tomography for individuals 50 to 80 years of age with a 20-pack-year history who currently smoke or quit within the past 15 years; discontinue screening once a person has not smoked for 15 years or develops a health problem that limits life expectancy

Osteoporosis screening19

- (B) Screen women 65 years and older
- (B) Screen postmenopausal women if increased fracture risk shown with an osteoporosis risk tool (e.g., 8.4% in 10 years by U.S. FRAX tool)
- (I) IETRFOA screening men

Abdominal aortic aneurysm screening²⁰

- (B) Screen men 65 to 75 years of age who ever smoked (100 or greater lifetime cigarettes) with one-time abdominal aortic aneurysm ultrasonography
- (C) Recommend selective screening of men 65 to 75 years who have never smoked

continues

CHD = coronary heart disease; CVD = cardiovascular disease; FRAX = Fracture Risk Assessment; IETRFOA = insufficient evidence to recommend for or against; PrEP = preexposure prophylaxis; USPSTF = U.S. Preventive Services Task Force.

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

Grade A/B Recommendations (with Associated Grade C/D/I Recommendations): (continued)

- (I) IETRFOA women 65 to 75 years of age who ever smoked
- (D) Recommend against routine screening in women 65 to 75 years of age who have never smoked

Unhealthy Drug Use Screening²¹

(B) Screen all adults older than 18 years for unhealthy drug use (by asking guestions, not biological specimens)

HIV prevention with PrEP²²

(A) Offer PrEP to persons at high risk of infection. See original text for considerations in patient selection

Primary prevention of breast cancer²³

- (B) Consider medications (such as tamoxifen, raloxifene, or aromatase inhibitors) that reduce risk of breast cancer in women at increased risk though with low risk of adverse effects
- (D) Recommend against routine use if no increased risk

Folic acid supplementation²⁴

(A) 0.4 to 0.8 mg daily for women capable of conceiving

Statins for primary prevention of CVD²⁵

- (B) Recommend low- to moderate-dose statin therapy in patients meeting all three criteria:
 - (1) 40 to 75 years of age
 - (2) Dyslipidemia, diabetes, hypertension, or smoker
 - (3) 10-year CVD risk of 10% or greater
- (C) Consider low- to moderate-dose statin therapy in appropriate candidates meeting the first two criteria but with a 10-year CVD risk of 7.5% to 10%
- (I) IETRFOA initiating statin therapy after 75 years of age for primary prevention

Aspirin for primary prevention of CVD and colorectal cancer²⁶

- (B) Recommend low-dose aspirin for patients 50 to 59 years of age with a 10-year CVD risk of 10% or greater, appropriate bleeding risk, and life expectancy of at least 10 years
- (C) Recommend individualized decision-making for patients 60 to 69 years of age who meet the same criteria
- (I) IETRFOA low-dose aspirin for patients younger than 50 years or 70 years or older

Fall prevention in community-dwelling older adults²⁷

- (B) Recommend exercise interventions for individuals 65 years and older at increased risk of falls
- (C) Recommend multifactorial interventions for appropriate individuals 65 years and older; see Clinical Considerations in original recommendation statement for patient selection
- (D) Recommend against vitamin D supplementation for fall prevention

Counseling to prevent sexually transmitted infection²⁸

(B) Recommend counseling to prevent sexually transmitted infection for adolescents and adults at increased risk

Counseling to promote healthy diet and physical activity²⁹

(B) Recommend that patients with other CVD risk factor(s) who are overweight or obese be offered or referred for intensive behavioral counseling

Counseling for skin cancer prevention30

- (B) Recommend counseling fair-skinned patients six months to 24 years of age about minimizing ultraviolet radiation
- (C) Recommend selectively counseling fair-skinned patients older than 24 years about minimizing exposure to ultraviolet radiation
- (I) IETRFOA counseling adults about skin self-examination

Counseling to promote healthy weight gain in pregnancy³¹

(B) Offer behavioral counseling interventions to promote health weight gain and to prevent excessive weight gain to all pregnant women

Grade C Recommendations:

Physical activity and healthy diet counseling to reduce cardiovascular risk in adults without obesity or known CVD risk factors³²

Prostate cancer screening with prostate-specific antigen testing in men 55 to 69 years of age after shared decision-making³³

Grade D Recommendations:

Bacteriuria (asymptomatic) screening in nonpregnant adults³⁴

Beta carotene or vitamin E supplementation for CVD or cancer risk reduction³⁵

Carotid artery stenosis screening³⁶

CVD screening with resting or exercise electrocardiography in low-risk patients $^{\rm 37}$

Chronic obstructive pulmonary disease screening with spirometry³⁸

Combined estrogen-progesterone for prevention of chronic conditions or estrogen for the same in patients with hysterectomy³⁹

Genital herpes screening⁴⁰

Ovarian cancer screening⁴¹

Pancreatic cancer screening⁴²

Prostate cancer screening with prostate-specific antigen testing in men 70 years and older³³

Testicular cancer screening⁴³

Thyroid cancer screening44

Vitamin D (\leq 400 IU) and calcium (\leq 1,000 mg) supplementation daily for primary prevention of fracture in postmenopausal women⁴⁵

Grade | Statements:

Atrial fibrillation screening with electrocardiography⁴⁶

Bladder cancer screening⁴⁷

Celiac disease screening⁴⁸

CVD screening in patients with nontraditional risk factors⁴⁹

CVD screening with resting or exercise electrocardiography in intermediate- to high-risk patients³⁷

Chronic kidney disease screening50

Cognitive impairment screening in older adults⁵¹

Gynecologic condition screening with pelvic examination⁵²

Hearing loss screening in older adults53

Illicit drug use screening⁵⁴

Impaired visual acuity screening in older adults⁵⁵

Multivitamin, single nutrient, or paired nutrients for CVD or cancer risk reduction (beta carotene and vitamin E, as above) 35

continues

CHD = coronary heart disease; CVD = cardiovascular disease; FRAX = Fracture Risk Assessment; IETRFOA = insufficient evidence to recommend for or against; PrEP = preexposure prophylaxis; USPSTF = U.S. Preventive Services Task Force.

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

Obstructive sleep apnea screening⁵⁶

Oral cancer screening57

Peripheral artery disease and CVD risk screening with ankle-brachial index $^{\rm 58}$

Primary open-angle glaucoma screening⁵⁹

Primary prevention of fractures with vitamin D and calcium supplementation (alone or combined; dose unspecified) in men or premenopausal women, and in postmenopausal women with daily dosages > 400 IU of vitamin D and > 1,000 mg of calcium⁴⁵

Skin cancer screening⁶⁰

Suicide risk screening⁶¹

Thyroid dysfunction screening⁶²

Vitamin D deficiency screening in community-dwelling nonpregnant adults 63

References

- U.S. Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(18): 1899-1909.
- 2. Siu AL. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2016;315(4):380-387.
- Krist AH, Davidson KW, Mangione CM, et al. Screening for hypertention in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2021;325(16):1650-1656.
- U.S. Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(11):1163-1171.
- Krist AH, Davidson KW, Mangione CM, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(3):265-279.
- Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infections in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2020;323(10):970-975.
- U.S. Preventive Services Task Force. Screening for HIV infection: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2019;321(23): 2326-2336.
- Krist AH, Davidson KW, Mangione CM, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;324(23):2415-2422.
- 9. Bibbins-Domingo K. Screening for syphilis infection in nonpregnant adults and adolescents: U.S. Preventive Services Task Force recommendation statement. *JAMA* 2016:315(21):2321-2327
- Bibbins-Domingo K. Screening for latent tuberculosis infection in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2016;316(9): 962-969.
- 11. U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for *BRCA*-related cancer: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2019;322(7):652-665.
- LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):902-910.
- 13. U.S. Preventive Services Task Force. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: U.S. Preventive Services Task Force final recommendation statement. *JAMA*. 2018;320(16):1678-1687.
- U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(7): 674-686.
- Sui AL. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861-868.
- Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(19):1965-1977.
- 17. Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2016;164(4):279-296.
- Krist AH, Davidon KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(10): 962-970
- U.S. Preventive Services Task Force. Screening for osteoporosis to prevent fractures:
 U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(24):2521-2531.

- Owens DK, Davidson KW, Krist AH, et al. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2019;322(22):2211-2218.
- Krist KH, Davidson KW, Mangione CM, et al. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;323(22):2301-2309.
- U.S. Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;321(22):2203-2213.
- 23. Owens DK, Davidson KW, Krist AH, et al. Medication use to reduce risk of breast cancer: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2019;322(9):857-867.
- 24. Bibbins-Domingo K. Folic acid supplementation for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(2):183-189.
- Bibbins-Domingo K. Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services recommendation statement. *JAMA*. 2016;316(19):1997-2007.
- 26. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2016;164(12):836-845.
- Grossman DC. Interventions to prevent falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(16):1696-1704.
- 28. Krist AH, Davidson KW, Mangione CM, et al.. Behavioral counseling interventions to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;324(7):674-681.
- Krist AH, Davidson KW, Mangione CM, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;324(20):2069-2075.
- Grossman DC. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(11):1134-1142.
- Davidson KW, Barry MJ, Mangione CM, et al. Behavioral counseling interventions for healthy weight and weight gain in pregnancy: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(20):2087-2093.
- 32. Grossman DC. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. JAMA. 2017;318(2):167-174.
- Grossman DC. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.
- Owens DK, Davidson KW, Krist AH, et al. Screening for asymptomatic bacteriuria 34 adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2019;322(12):1188-1194.
- 35. Moyer VA. Vitamins, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(8):558-564.
- 36. Krist AH, Davidson KW, Mangione CM, et al. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. *JAMA*. 2021:325(5):476-481.
- U.S. Preventive Services Task Force. Screening for cardiovascular disease risk with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(22):2308-2314.

USPSTF

Adult Preventive Health Care Schedule: Recommendations from the USPSTF (continued)

- Siu AL. Screening for chronic obstructive pulmonary disease: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(13):1372-1377.
- Grossman DC. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;318(22):2224-2233.
- Bibbins-Domingo K. Serologic screening for genital herpes infection: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2016;316(23): 2525-2530.
- 41. Grossman DC. Screening for ovarian cancer: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(6):588-594.
- 42. U.S. Preventive Services Task Force. Screening for pancreatic cancer. U.S. Preventive Services Task Force reaffirmation recommendation statement. *JAMA*. 2019;322(5):438-444.
- 43. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2011;154(7):483-486.
- 44. Bibbins-Domingo K. Screening for thyroid cancer: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(18):1882-1887.
- Grossman DC. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(15):1592-1599.
- Curry SJ. Screening for atrial fibrillation with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(5): 478-484.
- 47.Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in *Ann Intern Med.* 2011;155(6):408]. *Ann Intern Med.* 2011;155(4):246-251.
- 48. Bibbins-Domingo K. Screening for celiac disease: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(12):1252-1257.
- U.S. Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(3):272-280.
- 50. Moyer VA. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(8):567-570.
- 51. Owens DK, Davidson KW, Krist AH, et al. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2020;323(8):757-763.

- Bibbins-Domingo K. Screening for gynecologic conditions with pelvic examination: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(9):947-953.
- Krist AH, Davidson KW, Mangione CM, et al. Screening for hearing loss in older adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(12):1196-1201.
- Screening for illicit drug use [summary]. U.S. Preventive Services Task Force.
 Accessed July 1, 2015. http://www.uspreventiveservicestaskforce.org/ Page/Topic/recommendation-summary/drug-use-illicit-screening
- Siu AL. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(9):908-914.
- Bibbins-Domingo K. Screening for obstructive sleep apnea in adults: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(4): 407-414.
- 57. Moyer VA. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;160(1):55-60.
- 58. U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(2): 177-183.
- Moyer VA. Screening for glaucoma: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(7):484-489.
- Bibbins-Domingo K. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;316(4):429-435.
- 61. LeFevre ML. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(10):719-726.
- 62. LeFevre ML. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;162(9):641-650.
- Krist AH, Davidson KW, Mangione CM, et al.. Screening for vitamin D deficiency in adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(14):1436-1442.